Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Aclaris Therapeutics Inc (NASDAQ: ACRS) was $3.08 for the day, up 1.65% from the previous closing price of $3.03. In other words, the price has increased by $1.65 from its previous closing price. On the day, 0.68 million shares were traded. ACRS stock price reached its highest trading level at $3.145 during the session, while it also had its lowest trading level at $3.03.
Ratios:
Our analysis of ACRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 333703328 and an Enterprise Value of 240035344. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.20 while its Price-to-Book (P/B) ratio in mrq is 2.78. Its current Enterprise Value per Revenue stands at 15.248 whereas that against EBITDA is -3.651.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.42, which has changed by 0.11397064 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $3.47, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 21.84%, while the 200-Day Moving Average is calculated to be 69.99%.
Shares Statistics:
ACRS traded an average of 1.31M shares per day over the past three months and 1514770 shares per day over the past ten days. A total of 108.34M shares are outstanding, with a floating share count of 92.48M. Insiders hold about 14.64% of the company’s shares, while institutions hold 67.26% stake in the company. Shares short for ACRS as of 1764288000 were 4036730 with a Short Ratio of 3.09, compared to 1761868800 on 4233762. Therefore, it implies a Short% of Shares Outstanding of 4036730 and a Short% of Float of 4.44.
Earnings Estimates
Currently, 5.0 analysts are dedicated to thoroughly evaluating and rating the performance of Aclaris Therapeutics Inc (ACRS) in the stock market.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.29 and -$0.62 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.57, with 5.0 analysts recommending between -$0.3 and -$0.87.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $3.3M to a low estimate of $700k. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $9.21MFor the next quarter, 7 analysts are estimating revenue of $2.3M. There is a high estimate of $3.3M for the next quarter, whereas the lowest estimate is $1M.
A total of 7 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $9.83M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $7.7M. In the same quarter a year ago, actual revenue was $18.72MBased on 7 analysts’ estimates, the company’s revenue will be $6.83M in the next fiscal year. The high estimate is $13.2M and the low estimate is $900k.
